MTAP-Null瘤:综合脆弱性和治疗策略的全面审查
Bavani Subramaniam1, Wai Chin Chong1, Aylar Babaei1
1Brain Tumor Institute, Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC 20012, USA.
Cells
|December 24, 2025
概括
甲基氨酸酸化酶 (MTAP) 的同位素缺失发生在15%的癌症中,造成脆弱性. 本综述更新了MTAP损失发生率,其代谢影响和治疗策略,突出了针对性癌症治疗的挑战和未来方向.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 生物化学 生物化学
背景情况:
- 包括CDKN2A/B和甲基铁氨酸酸化酶 (MTAP) 基因在内的9p21.3位点的同卵性缺失影响了15%的人类癌症.
- 虽然CDKN2A是一种已知的瘤抑制剂,但MTAP在瘤发生中的作用取决于情境,影响 metionin 救援途径.
- 失去MTAP会造成合成漏洞,但有针对性的疗法在临床上取得了有限的成功.
研究的目的:
- 为各种癌症类型提供有关MTAP损失发生率的最新视角.
- 阐明MTAP损失对瘤代谢,免疫微环境和进展的影响.
- 总结针对MTAP-null瘤的临床前和临床治疗策略.
主要方法:
- 系统的文献审查和对MTAP在癌症中的损失现有数据的分析.
- 对研究MTAP缺乏瘤的治疗策略的临床前研究的评估.
- 对MTAP向抑制剂的临床试验现状的评估.
主要成果:
- 在各种癌症中,MTAP损失的综合发病率数据.
- 阐明MTAP损失对瘤代谢和免疫相互作用的影响.
- 针对MTAP向疗法的临床前发现和临床试验结果的摘要.
结论:
- 失去MTAP是一个重要的治疗目标,具有复杂的下游效应.
- 目前的MTAP向疗法面临局限性,需要改进策略.
- 未来的研究应该探索合理的组合疗法,可能超出PRMT5/MAT2A轴,以有效治疗MTAP无癌症.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Therapeutic Drug Monitoring: Affecting Factors
170
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
170
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


